| |
With the emergence of precision medicine and its focus on customizing treatment to individual patients, it may be possible to reduce the time to diagnosis for rare conditions, enabling identification and intervention at earlier stages of the disease – a hope that is new for rare disease patients. Explore this and more in our latest blog. Premier Research. Built for Biotech℠. .png)
|
|
Today's Big NewsMar 24, 2023 |
| By James Waldron After a number of high-profile SPAC announcements toward the end of last year, these deals once again dropped off in 2023. But that doesn’t mean the low-key revival of this reverse merger model has died. |
|
|
|
By Nick Paul Taylor Bioasis Technologies and Celyad Oncology are still waiting for better days. In separate updates, the two biotechs revealed that their respective turnaround strategies remain works in progress—and constraints on cash are still defining what can and cannot be achieved. |
By Nick Paul Taylor Relmada Therapeutics is preparing for one last roll of the dice. After blaming the failure of its first two phase 3 trials on an “unplausible placebo response,” the depression drug developer has sifted through the ashes of the flameouts and outlined plans to start a new study. |
Sponsored by DrugBank Data rich but quality poor. Massive amounts of disorganized data might be the final roadblock to unlocking the potential of data-centric AI. |
By Gabrielle Masson After laying off 95% of its team in January, Finch Therapeutics is pinching pennies to stay alive, extending its cash runway into 2025. |
By Helen Floersh A new drug to reduce inflammation in osteoarthritis has shown success in a double-blind study on animal models. The team behind it is now preparing to undertake a clinical trial that the U.S. Department of Defense will fund. |
By Max Bayer,Gabrielle Masson Co-founder and former CEO of Seagen Clay Siegall is back in the biopharma world less than a year after he was arrested and booked on fourth-degree domestic assault charges. |
By Teresa Carey This week on "The Top Line," we discuss Fierce Medtech’s annual Fierce 15 report and startups that made the cut. We also cover Illumina and Carl Icahn's proxy battle and more of this week's top headlines. |
By Heather Landi A hospital in Idaho plans to close down its labor and delivery unit, citing a loss of pediatricians, fewer births and Idaho’s legal and political climate around healthcare. As rural hospitals close maternity wards at an accelerating pace, could abortion bans worsen the trend? |
By Andrea Park Post-traumatic stress disorder treatment typically takes a two-pronged approach: talk therapy and medications combined to help manage symptoms. And now, a newly FDA-cleared device adds a third option in the form of self-guided neuromodulation. |
By Kevin Dunleavy The brief commercial run of Brii Biosciences' long-acting antibody combination of amubarvimab and romlusevimab is over. Brii will stop manufacturing the cocktail in China and has pulled its submission for emergency use authorization in the United States, the company said Friday. |
By Nick Paul Taylor Abbott is twisting my melon. For its latest campaign, the healthcare company’s concussion awareness coalition has created a family of melon-headed humanoids to tell Americans “if you hit your head, get it checked.” |
By Angus Liu Takeda detailed the psoriasis data behind its $4 billion deal for Nimbus Therapeutics' TYK2 inhibitor. Biohaven reached out to a Chinese company for a neuroinflammatory disease candidate. Astellas and Pfizer's Xtandi read out positively in early-stage prostate cancer, while the U.S. government denied a petition to grab the popular drug's patent. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss Fierce Medtech’s annual Fierce 15 report and startups that made the cut. We also cover Illumina and Carl Icahn's proxy battle and more of this week's top headlines. |
|
|---|
|
|
|
May 1 - 3, 2023 | Jersey City, NJ Don’t miss the opportunity to gain best practices in medical affairs strategy development and ensuring scientific materials are created and shared in a regulatory compliant manner to internal/external stakeholders and thought leaders. Register Today & save $200 from now until April 7th! .png)
|
|
Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
Executive Summary Read about the latest survey results from over 200 biopharma executives and the changing approaches to building biologic drug development pipelines. Sponsored by: Twist Bioscience |
Whitepaper Have you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here. Sponsored by: Aldevron |
Whitepaper Download Herspiegel Consulting’s Go-To-Market Model, based on 100+ launches, to learn the critical components, and timelines for commercial success. Sponsored by: Herspiegel Consulting |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
Research Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development. Sponsored by: Catalent |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
Whitepaper For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
Whitepaper How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Whitepaper Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| May 1-3, 2023 | Jersey City, NJ |
|
|
| |
|
